Bexobrutideg Clinical Trial Updates - Bexobrutideg demonstrates rapid and durable clinical responses in relapsed/refractory CLL, with updated findings from an ongoing Phase 1a study presented at EHA 2025[5,9] - Bexobrutideg shows high clinical activity and tolerable safety in an ongoing Phase 1a/b study in patients with Waldenström macroglobulinemia (WM)[5,9] - In CLL patients, the objective response rate (ORR) was 80.9% (95% CI: 66.7–90.9), with 1 (2.1%) complete response (CR) and 37 (78.7%) partial responses (PR)[24] - In WM patients, the objective response rate (ORR) was 84.2%, with 2 (10.5%) very good partial responses (VGPR) and 11 (57.9%) partial responses (PR)[47] Bexobrutideg Safety and Tolerability - Bexobrutideg is well-tolerated in patients with relapsed/refractory CLL, with purpura/contusion (45.8%), diarrhea (31.3%), and fatigue (31.3%) being the most common treatment-emergent adverse events (TEAEs)[22] - In WM patients, the most common TEAEs were petechiae (27.3%), diarrhea (22.7%), and purpura/contusion (18.2%), with a favorable safety profile and no new safety signals[45] Bexobrutideg Mechanism and Market Potential - Bexobrutideg is a novel small molecule BTK degrader that can overcome treatment-emergent BTKi resistance mutations and disrupt BTK scaffolding[15,54] - The total BTKi sales were $10.6 billion in 2024 and projected worldwide sales for BTK-targeting agents in CLL are expected to exceed $15 billion by 2028[75] - Nurix is advancing bexobrutideg in CLL with a first pivotal study to be initiated in 2025, positioned to lead a new class of therapeutics in CLL[66] Regulatory Designations - Bexobrutideg has received U S Fast Track Designation from the FDA for CLL (January 2024) and WM (December 2024)[62,61] - Bexobrutideg has received EU PRIME designation from EMA in November 2024[62]

Adaptive computing enables users to build the exact processing pipeline for their needs. With CPUs and GPUs, the compute pipeline is fixed. You can program with the instruction set, but cannot change how the instructions are implemented.With adaptive computing, you can build custom instruction sets and then control how each instruction is pipelined, potentially saving memory access and optimally balancing throughput and latency. Adaptive computing hardware may be optimized for specific applications and then ...

佳能开发的新一代图像传感器的试制品 佳能开发出了被称为"SPAD"传感器的新型图像传感器，在暗处表现出色，而且降低了耗电量。在车载 传感器领域，高附加值产品的全球市场份额由美国安森美、中国上海韦尔半导体旗下的美国豪威集团、 索尼半导体解决方案瓜分…… 日本佳能日前发布了用于汽车的高性能图像传感器。通过细致地测量光线，即使在漆黑的夜路上也能识 别远处的行人。在随着自动驾驶而增长的"汽车之眼"领域，索尼集团也在投入力量，开发竞争将日趋激 烈。 随着先进驾驶辅助系统（ADAS）和自动驾驶的普及，汽车传感器有望实现高增长。日本矢野经济研究 所的数据显示，2030 年市场规模将达到3.6929万亿日元，增至2024年的2.3倍。佳能瞄准的摄像头领域 到2030年将占整体的5成。 规定的严格化也成为东风。美国国家公路交通安全管理局（NHTSA）要求2029年9月以后上市的所有汽 车必须安装自动紧急制动系统，设置了系统昼夜运行等严格条件。 索尼产品可以检测较小的障碍物 挡在佳能前面的是CMOS传感器的巨人索尼集团。在车载方面，高附加值产品的全球市场份额（按金额 计算）由美国安森美、中国上海韦尔半导体旗下的美国豪威集团（Om ...

Looking for the best places to visit in Italy in 2025? These under-the-radar—and surprisingly affordable—towns were just named the most beautiful villages in Italy.Get the full list: https://t.co/HGLpZ1vZ0B(Photos: Getty Images) https://t.co/heVEavcccm ...

Agenda Kymera's Immunology Strategy Nello Mainolfi, PhD, Founder, President and Chief Executive Officer Oral Medicines with Biologics-like Activity Immunology Innovation Day May 9, 2025 STAT6 (KT-621) Update Jared Gollob, MD, Chief Medical Officer IRF5 (KT-579): Drugging a Genetically Validated Target Veronica Campbell, Senior Director, Immunology Question and Answer Session Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigati ...

January 2025 Revolutionizing Immunology: Oral Drugs with Biologics-Like Efficacy Science-driven clinical stage organization with industry-leading oral immunology pipeline J.P. Morgan Healthcare Conference Nello Mainolfi, Ph.D., Founder, President and CEO Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. These statements include, but are not limited to, implied and expr ...

6月28日，特斯拉宣布了在自动驾驶运营领域的新进展。视频显示，一台Model Y从位于美国得克萨斯 州奥斯汀的超级工厂出发，历时约30分钟穿越市区与高速公路，最高时速达到115公里，最终抵达客户 家门口，完成了一次"全自动交付"。 特斯拉首席执行官埃隆·马斯克在社交媒体上称，"据我们所知，这是全球首例在公共高速路上实现全程 车内无人、无远程控制的自动驾驶""这次交付是真正意义上的全自动驾驶"。 这次演示被视为特斯拉"完全自动驾驶"（FSD）系统的重大进步，也迅速引发了公众的激烈讨论：这是 自动驾驶发展史上的关键时刻，还是马斯克一贯擅长的又一次造势？ 技术表现亮眼，但规模化仍遥远 从技术角度来看，这一成果确实令人瞩目。美国Ainvest网站报道称，Model Y的自动交付路线涵盖复杂 的郊区道路与住宅街区，达到了L4级别的自动驾驶，即在特定条件下完全不需要人工干预，仅次于最 高等级L5。这一表现甚至优于谷歌旗下Waymo此前的无人驾驶测试。尽管Waymo已在美国多个城市提 供商业化服务，但其车辆仍需车内人员进行监督。 此次交付任务中，特斯拉FSD系统依靠其定制的神经网络芯片，结合包括摄像头、类激光雷达的数据 源 ...

🗞️ Corporations boost Bitcoin holdings by 18% for third straight quarter.🗞️ SEC approves Grayscale's GDLC for spot ETF conversion, holding BTC, ETH, XRP, SOL, ADA.🗞️ Coinbase acquires Liquify to streamline crypto token launches.@jennsanasie hosts "CoinDesk Daily." 🔗👇 https://t.co/HU2rFoJFFB ...

Uhum. Tá bem. Olá, meu nome é Ricardo Oliveira. Eu sou natural daqui da cidade de Vaselegre, Ceará. E hoje eu vou trabalhar o eh a questão de como a sociedade nos induz a pensar. Mas antes disso, eu vou contar um pouco da minha história. Eu nasci em um sítio isolado, não tinha acesso à escola e como vocês podem ver, sou deficiente físico. Eu uso a cadeia de rodas para me locomover. No entanto, a minha ao local onde eu morava não tinha acesso nenhum à escola, a estrada carrossal. E a gente também não tinha c ...

Ecosystem’s camera module and development tools are based on Microchip’s VS700 family of serializers and deserializers and will help Japanese OEMs speed ASA-ML adoption in ADAS applicationsCHANDLER, Ariz., July 02, 2025 (GLOBE NEWSWIRE) -- An automotive industry transition is underway to replace proprietary camera connectivity with solutions based on the open and interoperable Automotive Serdes Alliance Motion Link (ASA-ML) standard driven by over 150 member companies worldwide. To simplify and accelerate t ...